Ocugen Financials

OCGN Stock  USD 0.55  0.03  5.77%   
Based on the analysis of Ocugen's profitability, liquidity, and operating efficiency, Ocugen Inc is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. At this time, Ocugen's Common Stock Shares Outstanding is very stable compared to the past year. As of the 20th of March 2025, Non Current Liabilities Total is likely to grow to about 32.8 M, while Total Assets are likely to drop about 51.5 M. Key indicators impacting Ocugen's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio4.162.8572
Way Up
Pretty Stable
The essential information of the day-to-day investment outlook for Ocugen includes many different criteria found on its balance sheet. An individual investor should monitor Ocugen's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Ocugen.

Net Income

(56.76 Million)

  

Ocugen Stock Summary

Ocugen competes with Vaxart, Novavax, Rain Enhancement, Elevation Oncology, and Zura Bio. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing and Bharat Biotech for the commercialization of COVAXIN in the United States market. Ocugen operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS67577C1053
CUSIP67577C105 43358V109
LocationPennsylvania; U.S.A
Business Address11 Great Valley
SectorBiotechnology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.ocugen.com
Phone484 328 4701
CurrencyUSD - US Dollar

Ocugen Key Financial Ratios

Ocugen Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets27.4M105.8M108.6M64.5M82.4M51.5M
Other Current Liab2.9M4.0M8.3M2.8M15.5M16.3M
Net Debt(21.5M)(91.7M)(71.2M)(32.5M)(53.4M)(56.0M)
Retained Earnings(73.3M)(131.7M)(213.0M)(286.2M)(340.2M)(323.2M)
Accounts Payable395K2.3M8.1M3.2M4.2M3.0M
Cash24.0M95.0M77.6M39.5M58.5M39.7M
Other Current Assets1.8M15.4M7.6M3.5M3.2M3.0M
Total Liab5.8M9.9M24.6M24.0M52.8M55.5M
Total Current Assets25.9M102.6M98.5M43.0M61.7M44.0M
Common Stock1.8M2.0M2.2M2.6M2.9M3.1M
Other Assets474.2K432.1K2.0M177K203.6K193.4K
Long Term Debt1.8M1.7M2.3M2.8M27.3M28.7M
Capital Surpluse215.9M62.0M93.1M225.5M203.0M137.0M
Short Term Debt278K726K996K1.5M1.8M1.6M
Net Tangible Assets11.0M21.6M95.8M84.1M96.7M101.5M
Net Invested Capital23.6M97.5M86.3M43.4M58.3M42.6M
Net Working Capital22.3M95.6M80.0M25.9M40.1M40.3M

Ocugen Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense1.8M721.0K79K3.5M4.0M4.2M
Gross Profit36.3K(589K)(1.1M)5.3M4.1M4.3M
Operating Income(21.3M)(58.0M)(84.9M)(65.5M)(54.8M)(57.5M)
Ebit(21.1M)(58.6M)(84.9M)(65.5M)(59.0M)(61.9M)
Research Development6.4M35.1M49.8M39.6M32.1M25.1M
Ebitda(21.0M)(58.0M)(84.4M)(64.8M)(54.8M)(57.5M)
Income Before Tax(21.8M)(58.4M)(81.4M)(63.1M)(54.1M)(56.8M)
Net Income(22.6M)(58.4M)(77.8M)(63.1M)(54.1M)(56.8M)
Income Tax Expense801.5K(52K)(4.0M)536.1K482.5K506.6K
Interest Income20.0M1.2K1.1K16.1K14.5K13.7K
Cost Of Revenue6.4K589K1.1M704K633.6K649.2K
Net Interest Income(570K)(1.8M)(719.9K)(79K)(90.9K)(95.4K)

Ocugen Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash16.6M70.9M(17.5M)(38.1M)19.4M20.3M
Free Cash Flow(15.0M)(48.9M)(64.5M)(72.5M)(45.5M)(47.8M)
Depreciation102.1K229K480K704K2.0M2.1M
Other Non Cash Items7.6M799K1.1M4.3M(1.1M)(1.1M)
Capital Expenditures306.8K939K4.5M10.5M3.4M2.4M
Net Income(21.8M)(58.4M)(81.4M)(63.1M)(54.1M)(56.8M)
End Period Cash Flow24.2M95.1M77.6M39.5M58.8M39.8M
Net Borrowings5.3M(4.7M)(10K)500K450K676.9K
Change To Netincome5.8M8.2M7.7M11.6M13.3M14.0M
Investments(306.8K)(1.8M)(17.0M)3.1M(3.4M)(3.6M)

Ocugen Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Ocugen's current stock value. Our valuation model uses many indicators to compare Ocugen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ocugen competition to find correlations between indicators driving Ocugen's intrinsic value. More Info.
Ocugen Inc is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Ocugen's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ocugen's earnings, one of the primary drivers of an investment's value.

Ocugen Inc Systematic Risk

Ocugen's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ocugen volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Ocugen Inc correlated with the market. If Beta is less than 0 Ocugen generally moves in the opposite direction as compared to the market. If Ocugen Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ocugen Inc is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ocugen is generally in the same direction as the market. If Beta > 1 Ocugen moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ocugen Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ocugen's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ocugen growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.18

At this time, Ocugen's Price Earnings To Growth Ratio is very stable compared to the past year.

Ocugen March 20, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Ocugen help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ocugen Inc. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ocugen Inc based on widely used predictive technical indicators. In general, we focus on analyzing Ocugen Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ocugen's daily price indicators and compare them against related drivers.
When determining whether Ocugen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ocugen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ocugen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ocugen Inc Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.20)
Revenue Per Share
0.015
Quarterly Revenue Growth
(0.46)
Return On Assets
(0.47)
Return On Equity
(1.54)
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.